COVID-19’s Early Financing Fallout

article image

Venture-backed medtech companies are taking a pounding from COVID-19, and while VCs initially are pausing investment as they scramble to manage their portfolios through the chaos, they should find buying opportunities, particularly among later-stage companies.

As late as early March, 2020 looked to be a banner year for medtech venture financing. Now, the sector, along with much of the rest of the world, has come to a screeching halt and is clumsily digging out of an unprecedented economic and health disaster.

Articles from Wendy Diller: